All In Biotech

Drug Trial Radar · NCT06441643

Next Generation Rocklatan

A Phase II, Prospective, Two-Stage, Double-Masked, Randomized, Multi-Center, Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-17043 and PG043 (AR-17043/Latanoprost) Ophthalmic Solutions in Subjects With Elevated Intraocular Pressure

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 646 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

646

Actual

Start

Sep 4, 2024

Primary completion

Nov 14, 2025

Study completion Nov 14, 2025

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Conditions

  • Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • AR-17043 Ophthalmic SolutionDrug

    Investigational monotherapy

  • PG043 Ophthalmic SolutionDrug

    Investigational fixed dose combination

  • Latanoprost 0.005% Ophthalmic SolutionDrug

    Marketed monotherapy

  • Netarsudil 0.02% Ophthalmic SolutionDrug

    Marketed monotherapy

  • Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic SolutionDrug

    Marketed fixed dose combination

  • AR-17043 VehicleDrug

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean diurnal IOP at Day 8 (Stage 1)Time frame: Day 8 (8:00, 10:00, 12:00, 16:00)
  2. Mean diurnal IOP at Day 29 (Stage 2)Time frame: Day 29 (8:00, 10:00, 16:00)

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Trinity Research Group

    Dothan, Alabama

  • Eye Doctors of Arizona

    Phoenix, Arizona

  • Orange County Ophthalmology Medical Group

    Garden Grove, California

  • United Medical Research Institute

    Inglewood, California

  • Eye Research Foundation

    Newport Beach, California

  • North Bay Eye Associates

    Petaluma, California

  • Eye Center of Northern Colorado, PC

    Fort Collins, Colorado

  • Bruce A. Segal MD

    Delray Beach, Florida

  • Glaucoma Specialists of South Florida

    Delray Beach, Florida

  • Central Florida Eye Associates

    Lakeland, Florida

  • Mid Florida Eye Center

    Mt. Dora, Florida

  • Center For Sight

    Venice, Florida

  • Coastal Research Associates

    Roswell, Georgia

  • Moyes Eye Center

    Kansas City, Missouri

  • Rochester Ophthalmological Group

    Rochester, New York

  • James D. Branch Ophthalmology

    Winston-Salem, North Carolina

  • Bergstrom Eye Research

    Fargo, North Dakota

  • Midwest Eye Center

    Cincinnati, Ohio

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania

  • Carolina Eyecare Physicians LLC

    Mt. Pleasant, South Carolina

  • University Eye Specialists

    Maryville, Tennessee

  • Total Eye Care PA

    Memphis, Tennessee

  • Key-Whitman Eye Center

    Dallas, Texas

  • Piedmont Eye Center

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.